RecruitingPhase 1Phase 2NCT06885034

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

Sponsor

GlaxoSmithKline

Enrollment

320 participants

Start Date

Jun 11, 2025

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Neoplasms

Summary

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called GSK5764227, alone or in combination with other treatments, in people with advanced gastrointestinal cancers — specifically colorectal cancer and pancreatic cancer — that cannot be removed with surgery and have not responded to prior therapies. **You may be eligible if...** - You are 18 or older - You have advanced colorectal adenocarcinoma that has progressed after 1–2 prior lines of treatment, OR advanced pancreatic cancer that has progressed after 1 prior treatment line - Your cancer has at least one measurable area on imaging scans - You are in good overall health (ECOG 0 or 1) - You are able to provide a tumor tissue sample (fresh biopsy or stored tissue) **You may NOT be eligible if...** - Your cancer has not had prior treatment - You are not able to participate due to serious organ dysfunction or other medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALGSK5764227

GSK5764227 will be administered

Locations(47)

GSK Investigational Site

Los Alamitos, California, United States

GSK Investigational Site

Whittier, California, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Durham, North Carolina, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Wenatchee, Washington, United States

GSK Investigational Site

Heidelberg, Victoria, Australia

GSK Investigational Site

Melbourne, Victoria, Australia

GSK Investigational Site

Bonheiden, Belgium

GSK Investigational Site

Brussels, Belgium

GSK Investigational Site

Leuven, Belgium

GSK Investigational Site

Roeselare, Belgium

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

São Paulo, Brazil

GSK Investigational Site

Teresina, Brazil

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Sherbrooke, Quebec, Canada

GSK Investigational Site

Paris, France

GSK Investigational Site

Paris, France

GSK Investigational Site

Villejuif, France

GSK Investigational Site

Pisa, Italy

GSK Investigational Site

Aichi, Japan

GSK Investigational Site

Chiba, Japan

GSK Investigational Site

Hokkaido, Japan

GSK Investigational Site

Osaka, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

Amsterdam, Netherlands

GSK Investigational Site

Utrecht, Netherlands

GSK Investigational Site

Lrenskog, Norway

GSK Investigational Site

Oslo, Norway

GSK Investigational Site

Stavanger, Norway

GSK Investigational Site

Brzozów, Poland

GSK Investigational Site

Warsaw, Poland

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Pamplona, Spain

GSK Investigational Site

Santander, Spain

GSK Investigational Site

Zaragoza, Spain

GSK Investigational Site

Lund, Sweden

GSK Investigational Site

Stockholm, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06885034

Related Trials

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800156 locations

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT0666331910 locations

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT0721892684 locations

Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions

NCT017506191 location

Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers

NCT069964833 locations